Schall, Brown & Schwartz LLP has announced a class action lawsuit against ADMA Biologics for alleged securities violations including false statements, undisclosed related party transactions, channel stuffing to inflate revenue, and poor internal controls. The lawsuit covers shareholders who bought ADMA shares between August 9, 2024, and March 25, 2026. Investors who suffered losses during this period are encouraged to join the case before the August 10, 2026 deadline. The case has not yet been certified, and investors can participate without being lead plaintiffs to seek recovery of losses.
DJS Law Group announced a class action lawsuit against ADMA Biologics for alleged violations of securities laws, including making false statements and failing to disclose related party transactions. The lawsuit claims ADMA manipulated sales figures t...
Bernstein Liebhard LLP is investigating whether certain directors and officers of ADMA Biologics, Inc. breached their fiduciary duties to the company and its shareholders. The investigation aims to determine if the leadership acted in shareholders' b...
Berger Montague PC is investigating ADMA Biologics' Board of Directors for potential breaches of fiduciary duty related to alleged channel-stuffing practices. The firm suspects ADMA inflated revenue growth by pushing more of its flagship product, ASC...
